GSK3 inhibitors: Development and therapeutic potential
GSK3 inhibitors: Development and therapeutic potential
复制标题
DOI：
10.1038/nrd1415
复制
发表时间：
2004-06-01
影响因子：
120.1
通讯作者：
Goedert, M
中科院分区：
文献类型：
--
作者：
Cohen, P;Goedert, M
二十多年前，糖原合成酶激酶-3（GSK 3）最初被鉴定为参与控制糖原代谢的酶。近年来，它已被证明在调节多种细胞功能中具有关键作用，这促使人们努力开发GSK 3抑制剂作为治疗剂。在这里，我们描述了GSK 3的生物学相关的潜力作为糖尿病和神经退行性疾病的目标，并讨论GSK 3抑制剂的发展进展。
Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.